Millions of Americans have taken Ozempic and Wegovy to manage diabetes and for weight loss, with countless celebrities crediting their slim figures to GLP-1 drugs. But a growing number of patients claim Ozempic caused them to lose something they never expected: their eyesight.
The GLP-1 litigation involving allegations of blindness caused by semaglutide-based drugs like Ozempic is still in its early stages. However, in recent months, it’s become one of the fastest-growing pharmaceutical mass torts in the country.
This may be due in part to additional research studies released in 2026 connecting Ozempic to vision loss; many attorneys say the recent findings of increased risks of vision injuries among GLP-1 patients further validate the 2024 study results that sparked the first wave of blindness lawsuits.
Alongside the new research, the first Ozempic wrongful death case was filed in March, signaling an even more serious turn in the litigation involving GLP-1 weight loss drugs.
The Ozempic vision loss lawsuits are expected to continue to grow, just like the well-known GLP-1 stomach paralysis MDL that has over 3,700 cases. Given the vision injuries are permanent for most plaintiffs, the severity and long-term implications of what they’ve suffered (and will suffer in the future) is significant.
What are the Ozempic Vision Loss Lawsuits About?
The Ozempic blindness lawsuits focus on a condition called non-arteritic anterior ischemic optic neuropathy (NAION). It’s sometimes referred to as an "eye stroke".
NAION occurs when blood flow to the optic nerve is reduced, causing sudden vision loss that is often irreversible. Many patients report waking up with blurred vision, dark spots, or partial blindness in one eye.
What is thought to have sparked the Wegovy and Ozempic vision loss litigation was findings from a 2024 study published in JAMA Ophthalmology – a study that connected GLP-1 drugs to NAION. The Harvard Medical School researchers found that semaglutide users appeared to face a more than seven times higher risk of developing NAION compared to patients taking other medications.
As awareness of the lawsuits and research grew, the litigation gained momentum. In December 2025, cases were consolidated into the GLP-1 vision loss multidistrict litigation (MDL).
Plaintiffs allege that manufacturers, primarily Novo Nordisk (Ozempic, Wegovy), failed to adequately warn patients and physicians about the risk of vision injuries associated with their drugs. The central legal battle focuses on what manufacturers knew and when they knew it or if they should have known of the risks of NAION.
Novo Nordish denies the allegations and maintains that the benefits of the medications outweigh their risks.
New Research Links GLP-1 Drugs to Vision Loss
Since the initial findings published by Harvard Medical School in 2024, additional studies have continued to examine a possible connection between semaglutide and sudden vision loss.
A 2026 study published in the British Journal of Ophthalmology found that Wegovy users had a substantially higher reported risk of NAION than Ozempic users. Researchers emphasized that the study did not prove the drugs caused the condition, but the findings are still relevant because of the association between certain weight loss drugs and vision loss.
Another semaglutide research study published this year focused on veterans who took drugs like Ozempic to manage Type 2 diabetes. Researchers found those who took semaglutide medications had a 2-fold higher risk of experiencing NAION.
June 2026 GLP-1 Vision Loss Lawsuits Update
Just 21 lawsuits were consolidated when the GLP-1 vision loss MDL was centralized in the Eastern District of Pennsylvania in December 2025. As of June 2026, 110 cases alleging semaglutide weight loss drugs caused plaintiffs’ blindness are part of the MDL, a jump of nearly 25 since May. There are also numerous vision loss lawsuits proceeding in New Jersey state court, where Novo Nordisk is headquartered.
The vision loss lawsuits remain in the early discovery phase. A recent "Science Day" proceeding was scheduled to help the court understand the complex medical evidence concerning semaglutide and NAION. This was a crucial step, as the GLP-1 stomach paralysis MDL moves toward bellwether trial selection.
Ozempic Vision Loss vs. Stomach Paralysis Lawsuits
Most public attention surrounding GLP-1 litigation has focused on gastroparesis, often called stomach paralysis.
That MDL currently contains more than 3,700 lawsuits alleging Ozempic, Wegovy, and similar medications cause severe gastrointestinal injuries, including gastroparesis, bowel obstruction, and ileus.
But vision loss cases present a different challenge for drug manufacturers.
Many GI injuries can improve over time or be managed with treatment. NAION, by contrast, typically results in permanent damage. Plaintiffs who lost their vision may face lifelong limitations involving driving, employment, independence, and daily activities.
That permanence could make the Ozempic vision loss litigation particularly consequential if plaintiffs are able to establish the medications could have caused their injuries.
Why Consumers Should Pay Attention to Ozempic Lawsuits
GLP-1 drugs have become some of the most widely prescribed medications in the U.S., with millions of patients using them for diabetes and weight management. As usage expands, researchers continue identifying potential risks that may not have been fully understood when the drugs first entered the market.
The Ozempic and Wegovy lawsuits are still years away from any potential trial verdicts or settlements. However, it’s already prompted increased scrutiny from regulators, researchers, and courts.
Like other growing dangerous pharmaceutical mass torts in the U.S., the litigation has raised concerns about whether patients were given all the information they needed to make informed decisions about their health – and the medications they use to manage it.
For consumers taking GLP-1 weight loss and diabetes management drugs, it’s important to be aware of possible side effects not included on product warning labels. Any concerns should be brought up to your doctor.
If you think Ozempic, Wegovy, or a similar drug may have caused GI issues, vision loss, or any other injury, consider consulting with an experienced dangerous pharmaceuticals lawyer. An attorney can review your case and explain what legal options, if any, you have.
